| abstract |
Chimeric antibodies specific to human CD4 antigen are described, which contain the variable monkey sequence sequences of the human and human constant gamma 4 sequence or mutated forms thereof. These new antibodies, in contrast to the anti-CD4 antibody hitherto, essentially do not deplete T cell activity and possess additional therapeutic properties, such as antigenicity, good affinity for human CD4 and human antibodies. stability (biological and in vivo). Antibodies of the invention are suitable for use as a CD4 related disease, such as e.g. autoimmune disorders (rheumatoid arthritis, psoriasis, multiple sclerosis, etc.) and other illnesses such as e.g. leukemia, asthma, HIV infection and gave. |